Idexx Laboratories Stock News

Joel Isaacson & Co. LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 550 shares of the companys stock, valued at approximately $342,000. A number of other hedge funds and other institutional []

Investors are optimistic about IDEXX's (IDXX) better-than-expected results and continued international growth in the third quarter.

Ledyard National Bank decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 40.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 540 shares of the companys stock after selling 365 shares during the period. Ledyard National Banks holdings in IDEXX Laboratories were worth $336,000 []

Exchange Traded Concepts LLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,024 shares of the companys stock after selling 208 shares during the period. Exchange Traded Concepts []

Stratos Wealth Advisors LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.0% in the 3rd quarter, Holdings Channel reports. The firm owned 2,036 shares of the companys stock after selling 63 shares during the period. Stratos Wealth Advisors LLCs holdings in IDEXX Laboratories were worth $1,266,000 as of its most recent filing with []

First Bancorp Inc ME bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,170 shares of the companys stock, valued at approximately $1,350,000. IDEXX Laboratories makes up 1.3% of First Bancorp Inc MEs holdings, []

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP James F. Polewaczyk sold 4,595 shares of the stock in a transaction on Monday, November 29th. The stock was sold at an average price of $633.00, for a total value of $2,908,635.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the []

Analysts expect that IDEXX Laboratories, Inc. (NASDAQ:IDXX) will post sales of $779.98 million for the current quarter, Zacks reports. Four analysts have made estimates for IDEXX Laboratories earnings, with the highest sales estimate coming in at $785.00 million and the lowest estimate coming in at $771.20 million. IDEXX Laboratories posted sales of $720.94 million during []

Ardevora Asset Management LLP lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,100 shares of the companys stock after selling 200 shares during the quarter. Ardevora Asset Management LLPs holdings []

Winthrop Advisory Group LLC reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 350 shares of the companys stock after selling 27 shares during the quarter. Winthrop Advisory Group []

Equities analysts forecast that IDEXX Laboratories, Inc. (NASDAQ:IDXX) will report earnings of $1.67 per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for IDEXX Laboratories earnings. The highest EPS estimate is $1.69 and the lowest is $1.65. IDEXX Laboratories reported earnings per share of $2.01 during the same quarter last []

The companion animal diagnostics market was valued at US$ 2,031.62 million in2019 and is projected to reach US$ 2,684.86 million by 2027; it is expected to grow at a CAGR of 4.1%from 2020to 2027. Zoetis Inc., IDEXX laboratories, Inc, Thermo Fisher

LGT Capital Partners LTD. trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 95,280 shares of the companys stock after selling 2,990 shares during the quarter. IDEXX Laboratories accounts for about 1.8% of []

Old Port Advisors boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,002 shares of the companys stock after acquiring an additional 38 shares during the period. Old Port Advisors holdings in []